Steve Fischer
Analyst · Raymond James. Please go ahead
Thanks, Blake, and good morning. Net interest income was $155 million in the quarter, an increase of $8 million or 5% compared to the fourth quarter, driven by an $862 million or 4% sequential increase in average interest earning assets. Year-over-year net interest income increased $25 million or 19%, driven by $4.8 billion or 31% increase in average interest earning assets. Adjusting for the MSR valuation allowance, this strategic asset growth resulted in net interest income representing over 67% of total revenue in the quarter, compared to 62% a year ago. Net interest margin increased 9 basis points sequentially to 3.09%. The average yield on interest earning assets increased 2 basis points in the quarter to 3.99%, driven by a 3 basis point increase in portfolio residential loan yields, resulting from a 29 basis point increase in our Ginnie Mae pool buyout average yields. The asset rotation strategy of selling longer duration jumbo hybrid arms, to accommodate shorter duration government and short Ginnie Mae pool buyout loans, continues to perform well and is offsetting the headwind from the continued low rate environment. Commercial and commercial real estate loan yields declined 3 basis points in the quarter, while equipment financials declined 4 basis points. Total cost of interest bearing liabilities declined one basis point in the quarter, driven by lower average costs on time deposits and FHLB advances. Credit performance continues to be strong as non-performing assets declined to 40 basis points for the quarter. Our provision was $9 million for the quarter, flat sequentially and exceeded net charge-offs of $7 million or 16 basis points. Non-interest income was $33 million for the first quarter or $76 million when adjusting for the $43 million MSR valuation allowance incurred in the quarter. Approximately $15 to $20 million of the valuation allowance recorded in the first quarter is related to our retained core MSR due to a decline in the base mortgage rate which may be recovered overtime. The remainder represents expected losses resulting from the MSR sale transactions we announced today. Gain on sale of loans increased $8 million or 25% quarter-over-quarter to $43 million driven by higher lending volumes and an increase in margins. As we discussed last quarter, we have flexibility in our ability to manage our balance sheet and the duration of the assets we hold. During the quarter we sold forward approximately $770 million of longer duration jumbo hybrid arms, which is reflected in our elevated loans held for sale balance at the end of the quarter. These sales will settle in the second quarter as small gains. Non-interest expense increased $3 million or 2% to $156 million in the first quarter driven by a $5 million or 6% increase in salaries, commissions and benefits expense driven by the normal seasonal impact of higher benefits and payroll tax expenses. This increase was partially offset by lower occupancy and equipment expense in the quarter. G&A expense was $42 million, flat compared to the fourth quarter, with decreases in legal and professional fees and credit related expense, offset by increases in non-recurring consent order expenses. Our GAAP efficiency ratio was 83% for the first quarter. However, adjusting for the $43 million MSR valuation allowance, and other non-recurring items, our pro forma efficiency ratio was 66%, a 300 basis point improvement from 69% in the fourth quarter. In closing, I’d like to walk everyone through the financial impact of the MSR sale transactions. As we disclosed in the earnings release, we expect to realize a pre-tax loss of $40 million during the first and second quarters of 2015. The components include MSR impairments of approximately $27 million pre-tax, plus transaction costs and other accruals of approximately $13 million pre-tax. The $27 million MSR impairment was incurred in the first quarter as part of the MSR valuation allowance and we expect the remaining $13 million of transaction costs and other accruals to be incurred in the second quarter. Looking prospectively, we expect the pre-tax earnings accretions as a result of the transaction to be $2 million to $5 million in 2015, $8 million to $12 million in 2016 and $29 million to $35 million in 2017, driven by improved operational efficiencies as well as our ability to deploy the tier 1 capital created as a result of the transactions. More specifically, due to the [fading] impact on our MSR threshold deduction over the next three years under Basel III, we expect these sales to improve our tier 1 capital by $10 million to $15 million in 2015, $45 melon to $50 million in 2016 and $90 million to $95 million in 2017. Now I would like to turn it back over to Rob for some closing remarks.